Menü Logo

Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:305-10. doi: 10.1016/j.ejogrb.2014.07.046. Epub 2014 Aug 20.

Kajiyama H1, Mizuno M2, Shibata K2, Umezu T2, Suzuki S2, Yamamoto E2, Mitsui H2, Sekiya R2, Niimi K2, Kawai M2, Nagasaka T2, Kikkawa F2.
Author information 1Nagoya University, Graduate School of Medicine, Department of Obstetrics and Gynecology, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan. Electronic address: University, Graduate School of Medicine, Department of Obstetrics and Gynecology, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
Eur J Obstet Gynecol Reprod Biol
AbstractOBJECTIVES: This study was conducted to estimate the oncologic outcome of stage I epithelial ovarian carcinoma (EOC) patients after recurrence.STUDY DESIGN: After central pathological review and searching of the medical records of multi-institutions, a total of 103 relapsed patients with stage I EOC were analyzed. The major endpoint was postrecurrence survival (PRS).RESULTS: The median follow-up for surviving patients was 57.5 (5.7-242.0) months. The median age was 52 (14-89). Among the patients, 19 (18.4%) had FIGO IA disease, and 4 (3.9%) and 80 (77.7%) had IB and IC disease, respectively. Regarding the histological type, the clear-cell type was the most frequently observed (N=42: 40.8%). The 3/5-year overall and PRS rates of all patients were 63.7/47.9 and 38.2/24.0%, respectively. The 5-year PRS rates of patients with serous, endometrioid, clear-cell, and mucinous tumors were 44.9, 35.0, 19.8, and 0%, respectively. On stratifying by the histological type, the overall and postrecurrence survival rates of patients with the mucinous/clear-cell types were significantly poorer than in those with the non-mucinous/clear-cell types (OS: P=0.0253, PRS: P=0.0016). In multivariate analyses, the FIGO stage (IA/IB vs. IC) and histological type (clear-cell/mucinous vs. non- clear-cell/mucinous) retained their significance as prognostic factors of a poorer PRS {stage IC (vs.IA/B) HR: 2.176 (95% CI: 1.059-4.470), P=0.0343: clear-cell/mucinous (vs. non- clear-cell/mucinous): HR: 2.486(95% CI: 1.416-4.364), P=0.0015).CONCLUSIONS: Even if at stage I, once patients with a mucinous/clear-cell histology experience recurrence, subsequent survival is extremely poor.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Full Text Source: Elsevier Science
PMID:25203309 |

Um den vollständigen Inhalt zu sehen, müssen Sie sich einloggen oder sich auf registrieren.

Jetzt einloggen

Passwort vergessen

Jetzt kostenlos registrieren

Mit einer Anmeldung bei haben Sie Zugriff auf: DFP-Kurse, Arzneimittelinfos, Produktfortbildungen und mehr.

Loggen Sie sich ein oder registrieren Sie Ihren kostenlosen Account.